Synvisc Injection Buy Online
The entire 6mL syringe is the recommended dosage for a knee joint in a single session. Only certified physicians with experience and skill in intra-articular injection techniques can perform this procedure safely. Use aseptic techniques throughout the procedure to reduce risk of infection. Do not inject this solution into blood vessels or synovial tissues. Failure to do so might result in serious reactions like blood clots, severe inflammation, and stroke.
synvisc injection buy online
The injected hylan gel is metabolized by the body, just as hyaluronic acid is, making this a temporary solution to the treatment of osteoarthritis. A single injection of Synvisc One typically provides 6 months of relief from pain and discomfort, and the effects typically take effect a month after treatment. The duration of results will vary on an individual basis. If necessary, patients can opt for another bout of treatment about six months after the first session.
You can confidently suggest Synvisc One as one of the best injectable treatment choices for your patients, as it has been used by innumerable patients for close to 2 decades. This product has undergone important clinical trials, which attest to the efficacy and safety of this implant. However, some groups of people should steer clear of this intra-articular injection due to lack of clinical data regarding safe use, including:
In clinical trials, the most commonly reported adverse events were transient pain, swelling, and or joint effusion in the injected knee. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.
The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.
Synvisc injections are approved for the treatment of pain in patients with osteoarthritis who have failed to respond to a more conservative therapy, such as non-drug treatment options. Synvisc is considered to be a safe and effective means of treating pain and disability for people with osteoarthritis, when used appropriately, may help to postpone a surgery etc.
To start your patients on the path to better mobility, order Synvisc One online from Medica Depot. As well, you can buy Synvisc One wholesale by phoning, emailing, or faxing our friendly customer service team. When you purchase Synvisc One, you can help your patients find relief from their osteoarthritis symptoms with just 1 injection.
Synvisc One is an effective viscosupplement that replenishes the knee joint with a substance that mimics healthy synovial fluid. This restores the cushioning and shock-absorbing effects that have been lost with the development of knee osteoarthritis, thus providing pain relief to the patient. This particular treatment combines the conventional 3 Synvisc injection doses into 1 single dose, negating the need for multiple visits to the doctor for treatment.
Synvisc One is unique compared to other hyaluronic acid-based osteoarthritis treatments, because it takes just 1 Synvisc One injection to provide pain relief. It is also available in 2ml syringes, usually administering 3 injections into the knee joint, so you can tailor the treatment. Many patients experienced pain relief 1 month after their Synvisc One injection, although this may vary from person to person. Most patients will continue to experience osteoarthritis relief for about 6 months after their Synvisc One injection. As such, patients should return twice a year for additional treatments to continue living their active, pain-free lives.
Patients often turn to hyaluronic acid injections when other osteoarthritis treatments, such as anti-inflammatory and pain medications or physical therapy, no longer give them the relief they need. Other patients use Synvisc One injections to supplement their other osteoarthritis therapies, or to delay painful and invasive knee surgeries. With this, this injection allows a wide variety of osteoarthritis patients to live more active lives with less pain.
Some side effects of Synvisc One could include swelling, redness, bruising, pain, a feeling of heat, or fluid buildup in your patient's joint. Your patient may also experience a headache after Synvisc One injections. Generally, though, these side effects are mild and temporary. Synvisc One is made with hyaluronic acid, a substance similar to that naturally in your patient's synovial fluid. However, it is sourced from rooster combs, meaning that patients who are allergic to eggs or birds should refrain from using this product.
If you are not receiving satisfactory pain relief from your current medications for osteoarthritis, ask your doctor about Synvisc One. This is an injectable gelatinous fluid that will supplement your own natural synovial fluid that cushions the surface of your knee joint cartilage to allow smooth movement as you walk. There is no cure for osteoarthritis (OA), but treatment with Synvisc One can last up to six months and provide greater mobility and pain relief. A Synvisc One injection is done by your doctor during a regular office visit.
After your Synvisc One injection, you should return home and do not attempt any strenuous activities for 48 hours, including jogging, lifting heavy items, high impact sports, or standing for a long period of time. If you experience pain or swelling at home, apply ice to your knee for ten minutes at a time as needed. Call your doctor if the pain increases or swelling worsens.
Before trying Synvisc-One, tell your doctor if you have had an allergic reaction, such as swelling of the face, tongue or throat, respiratory difficulty, rash, itching or hives to SYNVISC or any hyaluronan-based products. Allergic reactions, some which can be potentially severe, have been reported during the use of Synvisc-One. Should not be used in patients with an infected knee joint, skin disease or infection around the area where the injection will be given, and should be used with caution when there is swelling of the legs due to problems with venous stasis or lymphatic drainage.
SYNVISC ONE (HYLAN GF 20) INJECTION(PFS) is not recommended for use in patients with infection of the knee joint, infection and diseases of the skin at the injection site and systemic bleeding disorders. Before receiving SYNVISC ONE (HYLAN GF 20) INJECTION(PFS), inform your doctor if you have severe inflammation of the knee, lymphatic or venous stasis (in the leg to be injected) and chondrocalcinosis (mineralization of hyaline cartilage).
The most common side effects of receiving SYNVISC ONE (HYLAN GF 20) INJECTION(PFS) are joint pain or inflammation, injection site pain, joint effusion and joints disease (arthropathy). Consult your doctor if any of the side effects worsen.
2. Huang TL, Chang CC, Lee CH, Chen SC, Lai CH, Tsai CL. Intra-articular injections of sodium hyaluronate (Hyalgan) in osteoarthritis of the knee. a randomized, controlled, double-blind, multicenter trial in the Asian population. NIH. National Library of Medicine, National center for biotechnology information. October 2011. [Accessed on 20th September 2022]
3. Guarda-Nardini, L., Masiero, S. and Marioni, G., 2005. Conservative treatment of temporomandibular joint osteoarthrosis: intra-articular injection of sodium hyaluronate. Journal of Oral Rehabilitation. September 2005. [Accessed on 20th September 2022] -2842.2005.01505.x
Synvisc One is a single dose treatment intended for injection in the knee, designed to treat osteoarthritis knee pain. It restores the elasticity and viscosity within the joint, allowing a more extensive movement of the joint. It supplements the fluid in the knee to help lubricate and cushion the joint.
Layout table for study information Study Type : Interventional (Clinical Trial) ActualEnrollment : 51 participants Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20) Actual Study Start Date : November 2011 Actual Primary Completion Date : October 2, 2017 Actual Study Completion Date : August 7, 2019 Resource links provided by the National Library of Medicine MedlinePlus Genetics related topics: Osteoarthritis MedlinePlus related topics: Osteoarthritis U.S. FDA Resources Arms and Interventions Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Arm Intervention/treatment Experimental: Synvisc-One Device: Synvisc-One (G-F 20)Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years. Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : "Worst Knee Pain" Likert Scale (0-10) Reported on Survey [ Time Frame: 26 weeks after injection at baseline ]Worst Knee Pain Scores were measured using a "Worst Knee Pain" Likert scale, the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain. 041b061a72